Advances in Knowledge
n After implementation of digital breast tomosynthesis (DBT), there were fewer recalls for asymmetries and more recalls for masses, calcifications, and areas of architectural distortion, with an overall 31% ( [9.3-6 .4]/9.3) decrease in the recall rate.
n At the time of additional imaging, fewer patients were evaluated with additional mammographic views (40.2% before DBT, 28.4% with DBT) and more were evaluated with US only (2.6% before DBT, 28.3% with DBT).
Implications for Patient Care
n DBT may decrease the recall rate without changing the biopsy positive predictive value and cancer detection rate.
n More patients can undergo US alone for additional evaluation, which improves the efficiency of the diagnostic evaluation.
T he use of digital breast tomosynthesis (DBT) has been increasing since its introduction into the U.S. market in 2011 following U.S. Food and Drug Administration approval. Early studies have shown a 15%-40% decrease in the recall rate (1-5) and a 9.5%-27% increase in the cancer detection rate (2, 5) . Given the frequently reported patient anxiety and healthcare costs (6) (7) (8) (9) associated with callbacks from screening mammography for additional imaging, a decrease in false-positive recall rates is welcomed. Improved detection of clinically relevant breast malignancies would also be beneficial, as treatment of early stage breast cancer is better tolerated and survival is improved. In addition, because DBT is not yet routinely available in all screening centers and necessitates additional radiation in comparison to digital mammography (DM) (10) and longer interpretation times (2, 11) , continued careful analysis of its performance is warranted. As with any new technology, it is important to study the results in clinical practice to confirm the utility and accuracy of new imaging techniques in a wide range of settings. To that end, the purpose of this study is to report our initial clinical experience with implementation of screening DBT and to compare the recall rates, types of abnormalities recalled, types of additional imaging performed at diagnostic evaluation, biopsy positive predictive value (PPV), and cancer detection rates with those of screening DM.
Materials and Methods

Study Design
In this Health Insurance Portability and Accountability Act-compliant, institutional review board-approved retrospective study, we reviewed all screening DM examinations performed from March 2011 through February 2012 and all screening DBT examinations performed from March 2012 through February 2013 at a dedicated breast imaging center. DBT was not used for diagnostic mammography. For the 2 weeks before March 1, 2012, only screening DM was performed with the two DBT units. Technologist training took place during those 2 weeks, and the number of screening DM examinations was limited to allow adequate time for training. Beginning March 1, 2012, screening DBT was performed with both units. Thus, an observational, abrupt switch, nonmatched pre-and/or post-DBT design was implemented whereby only DM was used for the 1st year and DBT was subsequently used for the 2nd year, without assignment or patient choice. Therefore, no systematic selection bias is anticipated. Physician staffing was unchanged during the study period. The requirement to obtain informed consent was waived. Examinations were reported with a mammography reporting system (PenRad; PenRad Technologies, Buffalo, Minn) by using standard Breast Imaging and Reporting Data System (BI-RADS) lexicon (12) . All studies were interpreted by one of six fellowship-trained breast radiologists (including A.P.L. and M.B.M.) with 4-16 years of clinical practice experience in mammography interpretation. All DM examinations were performed with one of three units (Senographe Essential, Senographe DS, or Senographe 2000D; GE Healthcare, Milwaukee, Wis), and all DBT examinations were performed with Selenia Dimensions units (Hologic, Bedford, Mass). All radiologists completed the required 8-hour tomosynthesis training before interpreting DBT studies. Screening mammograms were clearly separated from diagnostic mammograms, which were excluded from this study. All screening examinations were batch-read by using computer-assisted detection software (R2, version 8.7.215; Hologic). Thresholds for the computerassisted detection software were set by the manufacturer and were not altered. The software was unchanged during the course of the study.
For all patients with BI-RADS category 0 screening examinations (needs additional imaging), the electronic medical record was searched to determine the type of abnormality recalled, type of additional imaging performed at diagnostic evaluation, and results of additional imaging. For all screening cases that ultimately resulted in a BI-RADS category 4 or 5 assessment, the results from pathologic examination of any available biopsy specimens from screening-detected abnormalities were recorded, along with any corresponding results from specimens from surgical excision. For all BI-RADS category 3 cases, additional imaging results were recorded when available. Any available results from biopsy and surgical-pathologic examination were also recorded.
The recall rate was calculated by dividing the number of BI-RADS category 0 examinations by the total number of screening examinations performed during the study period. The biopsy PPV was defined as the number of BI-RADS category 4 or 5 biopsy specimens positive for malignancy divided by the number of BI-RADS 4 or 5 cases that underwent biopsy. The PPV for recall (13) was calculated by dividing the number of BI-RADS category 4 or 5 biopsy specimens positive for malignancy by the number of all positive screening examinations (BI-RADS category 0). The cancer detection rate was calculated by dividing the total number of malignancies identified during the study period, including BI-RADS category 3 cases that underwent biopsy and were malignant and high-risk lesions that were upgraded to malignancy at surgery, by the total number of screening examinations.
Information regarding patient risk factors was obtained from the mammography reporting system, where the number of high-risk patients (.20% lifetime risk of breast cancer with either Gail or Tyrer-Cuzick models) was identified for both the DM and DBT groups.
Statistical Methods
The two-proportion z test was used to test all differences between DM and DBT proportions. Confidence intervals (CIs) were also estimated by using the Score (Wilson) method with continuity correction for all sample proportion estimates, as well as the difference between the proportions. As a conservative effort, given the large sample size and possible violation of independence owing to the observational design, the critical value was set at 0.001. Because comparisons are restricted to before and after implementation of tomosynthesis, compounding of the a is not a concern. In addition, the specificity and PPV were estimated; the sensitivity and negative predictive value could not be estimated because follow-up was not conducted. Last, a two-sample t test was used to test for differences in age between DM and DBT groups. All data analyses were performed by using the base package in R 3.0.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Of the 12 577 DM and 12 921 DBT screening examinations performed during this study, 1175 and 827, respectively, resulted in a BI-RADS category 0 assessment. Of the patients with BI-RADS category 0 assessment, the average age (6stan-dard deviation) of patients who underwent DM was 54.6 years 6 10.7 (range, 29.4-90.6 years), and the average age of patients who underwent DBT was 55.3 years 6 10.8 (range, 30.9-89.4 years); the difference was not significant (P = .15). Patients with dense breasts (heterogeneously dense or extremely dense) comprised 63.3% (744 of 1175 patients) of the patients with BI-RADS category 0 assessment who underwent DM and 65.4% (541 of 827 patients) of the patients who underwent DBT. The recall rate was 9.3% (1175 of 12 577 examinations; 95% CI: 8.8%, 9.9%) for DM and 6.4% (827 of 12 921 examinations; 95% CI: 6.0%, 6.8%) for DBT (P , .00001), an overall reduction of 31%.
In the DM group, 733 of the 12 577 patients (5.8%) were at high risk for breast cancer (.20% lifetime risk with either Gail or Tyrer-Cuzick models); in the DBT group, 688 of the 12 921 patients (5.3%) were at high risk for breast cancer (P = .09).
The specificity and PPV for DM were 91.1% and 5.2%, respectively. After implementation of DBT, the specificity and PPV were 94% and 6.2%.
With DBT, there were fewer recalls for asymmetry and focal asymmetry and more recalls for calcification, distortion, and mass (Table 1) . With DBT, there was a decrease in additional imaging with mammography alone and an increase in additional imaging with US alone (Table 2) . Table 3 shows the outcomes from additional imaging in the DM group and the DBT group with BI-RADS category 0. More biopsies were recommended in the DBT group. For the DM group, 203 of the 216 BI-RADS category 4 or 5 lesions underwent needle biopsy and two underwent surgical excisional biopsy (Table 4) . Two high-risk lesions were upgraded to malignancy at excision. One benign biopsy was discordant, and invasive and in situ ductal carcinoma were identified at excision. Four patients were lost to follow-up. Seven patients did not undergo biopsy, but findings at imaging follow-up remained stable for 1 year. Biopsy PPV was 30.2% (62 of 205 examinations).
In the DBT group, 213 of the 227 BI-RADS category 4 or 5 lesions underwent needle biopsy and one lesion underwent surgical excisional biopsy (Table 4) . Nine high-risk lesions were upgraded to malignancy. Eight lesions were lost to follow-up. Five lesions did not undergo biopsy but underwent follow-up imaging that remained stable for 6 months. Biopsy PPV was 23.8% (51 of 214 examinations). In the DM group, five of the 251 BI-RADS category 3 lesions underwent biopsy instead of follow-up at the request of the patient or referring physician. Three biopsy specimens were classified as benign and two were classified as high-risk lesions. One of the high-risk lesions (atypical ductal hyperplasia) was upgraded to ductal carcinoma in situ. At follow-up, 205 of the 251 lesions initially classified as BI-RADS category 3 were assessed as benign, BI-RADS category 2; 20 remained as BI-RADS category 3 lesions; 10 were assessed as BI-RADS category 4 or 5 and underwent biopsy; and 11 were lost to follow-up. Two of the 10 lesions recommended for biopsy were malignant. The range of imaging follow-up for BI-RADS category 3 lesions in the DM group was 0-38 months (mean, 22 months; median, 24 months).
For DBT, six of the 208 BI-RADS category 3 lesions underwent biopsy instead of follow-up at the request of the patient or referring physician. All biopsies were benign. At follow-up, 82 were assessed as BI-RADS category 2, 18 remained as BI-RADS category 3, five were assessed as BI-RADS category 4 or 5 with recommendation for biopsy, and 97 were not yet due for follow-up imaging at the time of this review or were lost to follow-up. Three of the five lesions for which biopsy was recommended were benign, one lesion was a high-risk lesion that was not upgraded to malignancy at surgical excision, and one lesion did not undergo biopsy in our system. The range of imaging follow-up for BI-RADS category 3 lesions in the DBT group was 0-24 months (mean, 12.5 months; median, 12 months).
A comparison of outcomes for additional imaging of asymmetries, calcifications, masses, and architectural distortions with DM and DBT is shown in 
Discussion
We found that the recall rate significantly decreased by 31% (from 9.3% to 6.4%) with DBT, which is in keeping with findings from previous studies where the decrease in recall rates ranged from 15% to 40% (1) (2) (3) (4) (5) . The distribution of types of abnormalities recalled from screening was significantly different for DBT, with increases in recalls for masses, distortions, and calcifications and decreases in recalls for asymmetries and focal asymmetries. Studies performed in reader trials (3) have suggested that tomosynthesis would allow fewer asymmetries to be recalled, and our study confirms this in clinical practice.
Because of its pseudo-three-dimensional nature, DBT enables better assessment of superimposed breast tissue, which results in a decrease in the number of false-positive recalls due to summation artifact from overlapping tissue (14, 15) and better assessment of mass margins. Multiple studies (16) (17) (18) (19) have suggested that DBT could replace mammographic spot compression views for the evaluation of noncalcified lesions. The decrease in recalls for asymmetries and focal asymmetries with DBT may be related to improved characterization of overlapping breast tissue as a benign finding, which would reduce recalls for summation of overlapping tissue. It may also be related to improved visualization of mass margins. Masses obscured by adjacent glandular tissue at DM, for example, are likely recalled as asymmetries or focal asymmetries, whereas more detailed visualization of margins with DBT enables a more accurate characterization of the recalled lesion as a Kopans et al (23) reported equal or better visualization of calcifications with DBT, others (24) have noted DM to be slightly more sensitive than DBT for the detection of calcification. It may be that DBT enabled an improvement in the visualization of calcifications in our study. However, one confounding factor in our study is that DM and DBT were performed on machines made by different manufacturers with different digital detectors, which could also affect the conspicuity of calcifications.
Our study showed a significant change in additional imaging performed following a recall from screening, with fewer patients who undergo DBT undergoing additional mammographic views only and more undergoing US alone. This change in treatment, with a decrease in additional mammographic views, helps confirm findings from other studies (16) (17) (18) (19) that have suggested DBT could effectively replace additional mammographic views in clinical practice. The increased use of US alone is likely related to the improved assessment of mass margins with DBT. In cases where the mass margins are well seen with DBT, the patient may proceed to US without the need for additional mammographic views. This results in improved efficiency of the diagnostic evaluation and may decrease patient anxiety.
The biopsy PPV and cancer detection rate were similar for DM and DBT in this study. Although some studies (19, 25) have reported an increase in accuracy with DBT, our finding of comparable biopsy PPV is in keeping with those of other previously published studies (2, 26) . Multiple previous studies (2, 5, 15, 22, 26) have reported an increase in the cancer detection rates. However, all but one of those studies are from Europe, where screening is performed on a biennial basis. One would thus expect more cancers within a population screened every 2 years as compared with a population screened every year, as is common practice in the United States. These and other differences in patient populations may contribute to the differences in cancer detection rates in our study as compared with previous studies. The one study from the United States (5) showed mass. This would thus contribute to the increase in recalls for masses with DBT. Similarly, the increase in recalls for distortions is likely attributed to the three-dimensional nature of DBT, which enables better visualization of architectural distortion and its associated spiculations amid normal adjacent tissue. Architectural distortion has traditionally been one of the most challenging findings to identify at DM (20) , with substantial interobserver variability. However, one recent study (21) reported that DBT was more informative than DM in 94.4% of architectural distortions. Another small study (22) reported an increase in the sensitivity of DBT in cancers manifesting as spiculated masses and distortions.
The increase in recalls for calcifications has not been previously reported, as most studies about DBT have focused on noncalcified abnormalities. Although Note.-Data are numbers of cases. Numbers in parentheses are percentages.
* There was no biopsy follow-up for six cases. a 9.5% increase in the cancer detection rate with DBT, but this difference was not statistically significant. In addition, the number of patients in our study is likely too small to demonstrate a statistically significant difference in cancer detection (underpowered) with the introduction of DBT, given that only several cancers per 1000 women screened are expected. One limitation of our study is its retrospective design, which prevents causal inference from being drawn of our results. In addition, although there was no significant difference in the percentage of patients with a lifetime risk of more than 20% between the DM and DBT groups, there could be other differences in the patient populations that could affect the results. Accurate assessment of false-negative findings is also not performed because many patients have not yet returned for subsequent imaging. Differences in visualization of calcifications may also be related, at least in part, to differences in digital detectors between the two vendors used during this study.
In summary, our study showed a decreased recall rate without a change in biopsy PPV or cancer detection rate after implementation of DBT, along with fewer recalls for asymmetries and more recalls for masses, calcifications, and areas of architectural distortion. More patients were evaluated with US only, and fewer required additional mammographic views only at the time of additional imaging following DBT screening.
